Business context and reporting period
Minerva Neurosciences, Inc. filed this unaudited Form 10-Q for the quarter and six months ended June 30, 2014. The clinical-stage biopharmaceutical company reported no product revenue and no commercially approved products. Its development portfolio included MIN-101 (schizophrenia), MIN-117 (major depressive disorder), MIN-202 (insomnia) and MIN-301 (Parkinson’s disease). The period included the February 2014 acquisition of Mind-NRG; results also reflected the November 2013 Sonkei merger.
Financial performance and position
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $14.55 million; prior year $0.25 million | $15.14 million; prior year $0.35 million |
| General and administrative expense | $3.10 million; prior year $0.13 million | $5.13 million; prior year $0.30 million |
| Interest expense | $1.73 million; prior year none | $2.04 million; prior year none |
| Net loss | $19.37 million; prior year $0.38 million | $22.30 million; prior year $0.65 million |
| Basic and diluted loss per share | $2.55; prior year $0.10 | $3.07; prior year $0.17 |
Cash and cash equivalents were $0.48 million at June 30, 2014, down from $1.82 million at December 31, 2013. Total current assets were $0.51 million and current liabilities $10.05 million. Total assets were $52.96 million, including $34.20 million of in-process research and development (IPR&D) and $15.10 million of goodwill. Total liabilities were $23.72 million; stockholders’ equity was $29.23 million. The filing reports no gross margin because the company had no revenue.
For the six months, operating cash use was $3.78 million, investing cash provided was $1.17 million (cash acquired with Mind-NRG), and financing cash provided was $1.28 million, primarily from working-capital loans. The net decrease in cash was $1.34 million. Convertible notes had a $2.01 million carrying value and bridge loans were $1.38 million at quarter-end; the notes converted to shares and the bridge loans were repaid after quarter-end.
Material changes and unusual items
- Compared with 2013, operating expenses and losses rose sharply, reflecting the expanded portfolio, development activity, public-company preparation, and substantial non-cash stock compensation.
- Six-month stock-based compensation was $14.82 million, including approximately $10.5 million related to shares that became probable of vesting upon the IPO registration statement’s effectiveness. Debt-discount amortization contributed approximately $1.95 million of non-cash interest expense.
- The Mind-NRG acquisition was recorded at approximately $16.5 million, principally allocated to $15.2 million of IPR&D and $7.2 million of goodwill, with a $6.1 million deferred tax liability. Acquisition valuation allocations remained subject to refinement.
- The company completed its IPO on July 7, 2014: 5,454,545 shares were sold at $6.00 per share. It also received net proceeds from concurrent private placements, including a $19.7 million investment by a Janssen affiliate, and approximately $0.9 million from an over-allotment. The filing gives differing net-proceeds figures depending on whether specified expenses, debt repayment and license payments are deducted; it separately reports $25.2 million net from the IPO after those items, and $27.3 million before bridge-loan repayment and the ProteoSys payment.
- In July, Minerva paid Janssen a $22.0 million upfront fee for MIN-202 rights; the fee is expected to be expensed in the third quarter. Notes of approximately $2.0 million, including accrued interest, converted into 352,000 shares, and approximately $1.4 million of bridge loans were repaid.
Outlook, risks and contingencies
Management expects continued losses and negative operating cash flow, with R&D expected to be the largest and increasing expense category. The filing states that IPO and concurrent-placement proceeds, together with existing cash, were expected to fund projected operations through 2015, including planned MIN-101 Phase II development, MIN-202 Phase Ib work and MIN-301 preclinical development. Additional capital will be needed, particularly for MIN-117 and later development; financing may not be available on acceptable terms. The company’s recurring losses and limited pre-IPO resources raised substantial doubt about its ability to continue as a going concern.
Key risks include clinical efficacy and safety uncertainty, trial delays or enrollment challenges, regulatory approval and foreign-trial acceptance, reliance on CROs and contract manufacturers, intellectual-property protection and license milestones, competition, and the need for further financing. The company also disclosed material weaknesses in internal control over financial reporting, including inadequate segregation of duties, disclosure controls and risk assessment; remediation was ongoing. No material legal proceedings were reported as of June 30, 2014.
Important facts for investors to verify
- Post-IPO cash, cash runway and the company’s actual spending against its stated expectation of funding operations through 2015.
- How the $22.0 million MIN-202 license payment and ongoing development-cost commitments affect liquidity and future R&D expense.
- Clinical progress, timelines and funding needs for MIN-101, MIN-117, MIN-202 and MIN-301, including applicable license milestones and termination rights.
- Final acquisition purchase-price allocations, IPR&D and goodwill impairment assessments, and the potential impact of the large stock-compensation charges.
- Progress in remediating the disclosed internal-control material weaknesses and any updated going-concern assessment.